newsfilter
← Latest News
GlobeNewswire·

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

  • Ascentage Pharma presented Phase Ib/II study data for Lisaftoclax (APG-2575) combined with azacitidine at the 67th ASH Annual Meeting in Orlando, Florida.
  • The study enrolled 103 patients with newly diagnosed or prior venetoclax-exposed myeloid malignancies, including AML, MPAL, CMML, & higher-risk MDS.
  • Preliminary evidence indicates Lisaftoclax can overcome venetoclax resistance, achieving a 31.8% overall response rate (ORR) in 22 evaluable venetoclax-exposed patients.
  • An 80.0% ORR was achieved in 15 evaluable patients with newly diagnosed higher-risk MDS/CMML, including 40% complete response & 40% marrow complete response.
  • The combination regimen demonstrated a strong safety profile with no dose-limiting toxicities reported across all patient cohorts.
  • Common grade ≥3 treatment-emergent adverse events included neutropenia (41.7%), febrile neutropenia (35.0%), thrombocytopenia (26.2%), & anemia (17.5%).
  • Median overall survival was 7.6 months for relapsed/refractory AML/MPAL & 11.3 months for relapsed/refractory higher-risk MDS/CMML.
  • Lisaftoclax is an orally administered Bcl-2 selective inhibitor approved in China for adult patients with CLL/SLL who have received prior systemic therapy.
  • Ascentage Pharma is conducting four global registrational Phase III trials for Lisaftoclax in CLL/SLL, AML, & higher-risk MDS.
  • The drug is currently under investigation by the FDA & has not yet been approved for use in the U.S. market.